The author has disclosed that she has no fi nancial interests to any commercial company related to this educational activity. I t has been well established that after major orthopaedic surgery, patients are at high risk for developing venous thromboembolism (VTE) and therefore, VTE prophylaxis is considered standard of care ( Hou, 2011a ; Hull, Yusen, & Bergqvist, 2009) . Controversies exist as to the safest and most clinically relevant methods for VTE prevention. Choices of VTE prophylaxis methods are based primarily on risk versus benefi t along with considerations of cost and convenience. The primary benefi t of thromboprophylaxis is the prevention of deep vein thrombosis (DVT) and subsequent pulmonary embolism (PE; Geerts et al., 2008) . Despite guidelines and regulations, the full impact of VTE and its status as the leading cause of a preventable
Patients who have major orthopaedic surgery are at high risk for developing venous thromboembolism (VTE). Assessment of risk and treatment to prevent VTE are considered standard of care due to its signifi cant morbidity, potential mortality, and clinical burden and cost. Guidelines are available aiding orthopaedic surgeons to choose the best methods of VTE prophylaxis. Optimal VTE prevention has not been achieved. Recent advances in the understanding of the coagulation cascade have evolved because of a novel understanding of the molecular infl uences on the coagulation pathway. Subsequently, new anticoagulants have been developed that target specifi c factors within the coagulation cascade that are contrasted to the currently used agents that have a broad effect on the coagulation pathway. Multiple clinical trials have tested the new anticoagulants within the orthopaedic total knee and total hip arthroplasty arena. In addition, research to fi nd new ways to prevent VTE was driven by limitations of the currently available agents. The new oral anticoagulants extensively trialed in orthopaedics are dabigatran, rivaroxaban, and apixaban. Clinical trials indicate that the new oral agents have the potential to impact VTE prophylaxis in regard to effi cacy, predicta bility and consistency, clinical monitoring, adherence as to use and duration, and convenience. Concerns persist regarding issues of bleeding complications, liver enzyme elevation, patients with renal disease, and drug-to-drug interactions. The new oral agents do not have an antidote to reverse bleeding effect and have no reliable assay to measure effect. Nurses need to be aware of these new VTE prophylactic choices and their implications in order to provide the best outcomes for their patients.
hospital-acquired complication remain unrecognized (Haas, Barrack, Westrich, & Lachiewicz, 2008) . Without the use of effective thromboprophylaxis, DVT occurs in approximately 40%-60% of patients with total hip replacement (THR), total knee replacement, and hip fractures . Anderson, Hirsh, White, and Fitzgerald (2003) found that approximately 10% of total joint patients received inadequate thromboprophylaxis while in the hospital and approximately 33% received inadequate thromboprophylaxis postdischarge.
Consequences of not preventing VTE are many. In the short term, the presence of DVT can result in a PE, which can be fatal . Pulmonary embolism is considered the number 1 preventable cause of hospital death (Trujillo, 2010) . Long-term, clinical sequelae of VTE can be signifi cant and disabling manifested through consequences of postthrombotic syndrome, venous stasis ulcers, recurrent VTE, and pulmonary hypertension ( Caprini et al., 2003 ; Cohen et al., 2007 ; Heit et al., 1999 ) . The sequelae of long-term complications from a primary DVT pose a substantial economic burden along with decreased quality of life ( Hou, 2011b ) . The economic burden of managing acute and chronic VTE is signifi cant, especially if complications require rehospitalization, prolonged hospital stays, and long-term therapy and monitoring ( Hou, 2011b ) .
regarding VTE prevention modality choice after total hip and total knee arthroplasty and are the American Academy of Orthopaedic Surgeons (AAOS) guidelines published in 2007 and the American College of Chest Physicians (ACCP) guidelines published 25 years ago and updated every 3 years (Eikelboom, Karthikeyan, Fagel, & Hirsh, 2009; Hou, 2011b ; Trujillo, 2010) . A notable difference between the two guidelines, as stated by Eikelboom et al. (2009) , is related to outcome criteria. The AACP research measured for DVT, both symptomatic and asymptomatic. The AAOS measured outcomes for symptomatic PE and fatal PE. The variant outcome criteria created a major point of disagreement as to whether DVT can be defi ned as a substitute for PE in measurement of complications ( Hou, 2011a ) . Another very important difference between the two guidelines to orthopaedic surgeons is that the AAOS also considered the effects of anticoagulants for serious joint bleeding and wound drainage ( Hou, 2011a ) .
In regard to adherence to one guideline or the other, a study by Markel et al. (2010) of the American Association of Hip and Knee Surgeons investigated practice patterns of joint arthroplasty surgeons. The authors found through their survey that 74% of the hospitals recognized the AACP guidelines; however, 68% of the orthopaedic surgeons reported that they preferred to follow the AAOS guidelines for VTE prophylaxis after total hip and knee arthroplasty. Hou (2011a) states that because of increased hospital quality and safety committee regulations, accountability for accreditation, and government groups weighing in, orthopaedic surgeons focus more on absence of VTE as an outcome.
Friedman, Gallus, Cushner, FitzGerald, and Anderson (2008) found that adherence to guidelines in regard to start time, duration, and intensity of VTE prophylactic therapy after major orthopaedic surgery is relatively low. Considerable confusion persists regarding guideline utility creating barriers to VTE prophylaxis (Haralson, 2008) . Barriers for poor compliance of the ACCP guidelines as outlined by Caprini and Hyers (2006) include lack of familiarity with recommendations, overestimation of bleeding risk, underestimation of thrombotic risk, and system limitations. Friedman (2010) cites that another potential barrier for optimal use of anticoagulants in orthopaedics may be due to inconvenience of use issues for the currently prescribed agents. Also, when considering benefi t versus harm, as Trkulja and Kolundzic (2010) state, pivotal effi cacy/ safety trials of VTE prophylaxis after major orthopaedic surgery are conducted mostly for regulatory purposes and do not include patients who have preexisting risk factors for either VTE or bleeding and therefore do not represent real-life situations. The authors state that the association of DVT and PE in major orthopaedic surgical patients may be weaker than that in other sicker patient populations and that strategies recommended may not fi t the orthopaedic patient.
Despite guideline recommendation and system regulations, bleeding risk continues to be a huge concern among orthopaedic surgeons when considering treatment with an anticoagulant to prevent VTE. Both Friedman (2010) and Hou (2011a) have identifi ed that postoperative bleeding complication is the number 1 risk that orthopaedic surgeons regard when choosing prophylactic VTE protection. In regard to the specifi c issue of bleeding, Deitelzweig et al. (2008) relay that orthopaedic surgeons regard bleeding at the surgical site and within the replaced joint space as the top bleeding concerns. Levy, Key, and Azran (2010) acknowledge that anticoagulants may potentiate bleeding so it is important for surgeons to understand the implications. In addition, concern about bleeding is warranted as bleeding caused by perioperative antithrombotic agents can pose a serious risk for those patients receiving neuroaxial anesthesia as the risk of a spinal hematoma is increased 15 times when anticoagulants are not used with precaution (Rosencher, Bonnet, & Sessler, 2007) . The development of a spinal hematoma can lead to permanent paralysis (Levy et al., 2010) . Because of the limited awareness of the true burden of VTE combined with the fear of bleeding, the use of thromboprophylaxis has been suboptimal in orthopaedic surgical patients . In response to the bleeding risk, Dahl and Bergqvist (2002) relay that in the United States, some surgeons are more concerned about bleeding than thromboprophylaxis. In addition, according to the authors, to further confuse the issue of bleeding risk, international standards are lacking on how to measure perioperative bleeding and bleeding related to the use of anticoagulants. Interpretations of bleeding complications are problematic because of the wide range of major bleeding defi nitions in studies, which make it diffi cult to compare risk. Specifi c to this problem, Hull et al. (2009) state that there are 10 different terms in the literature to describe bleeding events. Also, studies do not report bleeding events that are of relevance to orthopaedic surgeons (Hull et al., 2009) .
Several regulatory agencies, government offi ces, and consumer groups have mandated VTE prophylaxis for hospitalized patients. In 2008, the Centers for Medicare & Medicaid Services declared VTE after surgery a never event and will no longer reimburse costs associated with the subsequent hospital-acquired complications ( Hou, 2011b ) . In addition, The Surgical Care Improvement Project was initiated in 2006 with the overall goal, by 2010, to reduce the incidence of VTE in surgical patients by 25% ( Hou, 2011b ) .
Shortcomings of the Currently Used Agents
Pharmacologic VTE prophylactic agents that are currently used have been proven to be effi cacious in orthopaedics in the United States. These include the following: an oral vitamin K antagonist (VKA) as warfarin; the low-molecular-weight heparins (LMWH) as enoxaparin, dalteparin, and tinzaparin; and the synthetic pentasaccharide as fondaparinux Lassen & Laux, 2008 
The New Oral Anticoagulant Targets on the Coagulation Cascade
Concepts regarding thrombi creation are complex. New understandings are emerging and evolving. Modern theories of blood coagulation began in the 1940s (Riddel, Aouizerat, Miaskowski, & Lillicrap, 2007) . Comprehension of blood coagulation has recently rapidly evolved because of new insight into the understanding of the molecular orchestration of coagulation, isolation and characteristics of antithrombotic proteins, and advances in recombinant DNA technology (Eriksson & Quinlan, 2006; Weitz, Hirsh, & VTE prophylaxis following total knee or total hip arthroplasty .
Vitamin K antagonist has been used as the major anticoagulation agent for nearly 60 years, and warfarin has been the only oral VKA agent available in the United States ( Friedman, 2010 ) . Warfarin was approved for clinical use in 1954 and has since become one of the most prescribed drugs in the world (Mazza & Yale, 2009 ). Unfractionated heparins were developed more than 70 years ago and LMWH were developed in the 1980s (Hirsh, O'Donnell, & Eikelboom, 2007) . Fondaparinux, as a synthetic pentasaccharide, was approved for use in the United States in 2001 (Lassen & Laux, 2008 ) .
The current-generation thromboprophylactic agents have been identifi ed not only as being effi cacious, having good benefi t to risk ratios, but also as having significant drawbacks . Additional issues with the currently used anticoagulants are that they require therapeutic management and monitoring. In regard to monitoring the effects of warfarin, a study by Ansell et al. (2008) demonstrated that less than 50% of patients using warfarin are within the international normalized ratio (INR) therapeutic range of 2-3 placing many patients at risk for bleeding or thrombosis, depending on the INR level. Although the study by Ansell Samama, 2008). Coagulation factors, as discovered, were designated by roman numerals. The numeric system of numbering is not representative of a relationship between factors but is based on the timing and sequence of discovery. Within the system of coagulation numeration, the suffi x "a" indicates the activated form (Riddel et al., 2007) . The development of the new oral anticoagulants stems from discoveries of small molecule inhibitor coagulation enzymes. These new discoveries have been described as blockers of specifi c coagulation enzymes at their catalytic pocket that led to the formulation of the new anticoagulants (Zikria, Ansell, & Ansell, 2009 ).
The major difference of these new oral agents is the mechanism of action and how they are metabolized ( Ansell, 2007 ; Friedman, 2010 ) . Vitamin K antagonists or heparin-related compounds have a broad effect on multiple coagulation factors. In contrast, the new anticoagulants directly target and neutralize a specifi c coagulation factor. To alleviate some of the unpredictable behavior and the broad effect of VKAs and unfractionated heparins, recent research has focused on the single coagulation factors, namely thrombin (IIa) and factor Xa ( Ansell, 2007 ) . The thrombin and factor Xa inhibitors are the most advanced in clinical development (Sattari & Lowenthal, 2010) . Each of the new oral anticoagulants selectively inhibits central coagulation protein enzymes (Steffel & Lüscher, 2009 ). Simply explained, within the coagulation cascade, the contact pathway (intrinsic pathway) and the tissue factor pathway (extrinsic pathway) combine to activate thrombus formation. When the two pathways converge, it leads to the formation of factor Xa, transforming prothrombin to thrombin, which then activates the fi nal common pathway. The fi nal common pathway ultimately leads to the formation of fi brin and insoluble fi brin (Riddel et al., 2007) . Development of the new anticoagulants followed the logic that inhibition of any enzyme within the coagulation cascade should potentially reduce the formation of a clot (Riddel et al., 2007) . Refer to Figure 1 for sites of action of the new factor IIa and Xa inhibitors.
Clinical Development and Clinical Trials of the New Oral Anticoagulants
The three new oral anticoagulants that have been clinically trialed to prevent VTE after major orthopaedic surgery are dabigatran, rivaroxaban, and apixaban. These novel agents are direct and specifi c target inhibitors of thrombin (IIa) or factor Xa.
Because of the morbidity and mortality associated with VTE and because it is considered to be preventable after surgery, massive research has been conducted into the pathogenesis of thrombotic disease leading to the discovery of new oral anticoagulants (Tsiara, Pappas, Boutis, & Laffan, 2011) . Two general reasons for the development of the new anticoagulants include (1) alleviating concerns regarding the risk-benefi t ratio and (2) reducing inconvenience and limitations of the currently used agents . They were also developed to ensure that they would be at least as effective and that they would pose as equal or less of a risk for bleeding as the VKAs and heparins (Wietz et al., 2008) . Some of the desirable characteristics of the new agents, as noted in the literature, include that they (1) are administered in fi xed doses because of predictable pharmacokinetics, (2) do not need a bridge of rapid-acting parenteral anticoagulant as they have a rapid onset of action, (3) do not require serum laboratory monitoring, and (4) have few drug-drug and drug-food interactions Zikria et al., 2009 ). For more specifi c characteristics of an ideal anticoagulant, refer to Table 2 .
Orthopaedics has been the testing ground for the development of these new anticoagulants. Researchers have established that orthopaedic patients are at high risk for VTE without antithrombotic treatment and are a well-defi ned group . In addition, the elective nature of major orthopaedic surgery assists with protocol adherence. Patients are usually medically optimized and therefore survive the surgery. Moreover, there are specifi c, defi ned outcomes for both effi cacy and safety of treatment (Eriksson & Dahl, 2004; Eriksson & Quinlan, 2006) . Research is also robust regarding antithrombotic medication within the orthopaedic perioperative period due to the large volume of major orthopaedic surgeries. Kurtz et al. (2005) share that in 2005, there were approximately 250,000 THRs, and they estimate that by 2030, the number will increase by 174% to 572,000. Also, unlike chronic medical conditions that require a lifetime of antithrombotic treatment, the research timeline in orthopaedics is more manageable.
Ximelagatran, a direct thrombin inhibitor, was the fi rst oral drug developed in the new class of anticoagulants (Vaughn, 2005) . It was trialed in comparison with warfarin and enoxaparin and was initially approved for use by the European Medicines Agency based on trial results in orthopaedic total joint arthroplasty (Hou, 2011a) . It held promise as the initial results, indicating that it was at least as effective as warfarin and enoxaparin. However, longterm use demonstrated that ximelagatran was associated with hepatotoxicity and failed the FDA approval (Merli, Spyropoulos, & Caprini, 2009) .
Besides dabigatran, rivaroxaban, and apixaban, there are many other new oral anticoagulants in clinical trials and in development. Dabigatran, rivaroxaban, and apixaban have received the most attention due to the extensive nature of their clinical trials (Trujillo, 2010) . Numerous trials, most with large sample sizes, have been conducted testing dabigatran, rivaroxaban, and apixaban, all comparing the new agents against enoxaparin after total hip and total knee arthroplasty in both the United States and Europe during the years 2000-2010. Each of these new agents has been studied in Phase III trials. According to Halperin (2009) , the FDA and the European Medicines Agency regulate the guidance for the development, design, and evaluation of the trials. Both agencies base their approval decisions on the results of the Phase III trials. According to U.S. National Institutes for Health (2011), in Phase III trials, the number of subjects ranges from 1,000 to 3,000. Trial purposes were to confi rm effectiveness, monitor for side effects, make comparisons to commonly used treatments, and ensure safety during the trials ( Halperin, 2009 ( Hou, 2011a ( Hou, , 2011b . As recently as of July 1, 2011, the FDA has approved rivaroxaban, marketed as Xarelto, to be used for total hip and knee VTE prophylaxis (U.S. Department of Health Human Services, 2011a). The use of rivaroxaban was approved for the same indication in both the Canada and the European Union in 2008 ( Hou, 2011a ( Hou, , 2011b ). Apixaban has not been approved for use for any indication or in any country thus far ( Hou, 2011a ( Hou, , 2011b .
For details of the names of the Phase III trials for dabigatran, rivaroxaban, and apixaban, refer to Table 3 . All Phase III trials researched the new oral anticoagulants against enoxaparin after major orthopaedic surgery and measured for composite VTE. There were two separate primary outcomes for the phase III trials. One was primary effi ciacy measured as composite VTE and all cause mortality. The other outcome was primary safety measured as major bleeding, although bleeding defi nitions varied somewhat among trials (Trujillo, 2010; Ufer, 2010) . Length of treatment and dosage of enoxaparin varied between the trials on the basis of the type of major orthopaedic surgery. Trials also varied according to regimen recommendations for location of either Europe or the United States, dependent on the type of surgery (Trujillo, 2010) .
Summaries of the Phase III Trials: Primary Effi cacy and Primary Safety Outcomes
When data from the Phase III trials were studied separately and as pooled results, conclusions varied somewhat 
Note . All tested for primary effi cacy outcome as composite VTE and all-cause mortality during treatment and for safety outcome as incidence of major bleeding. THA ϭ total hip arthroplasty; TKA ϭ total knee arthroplasty; VTE ϭ venous thromboembolism.
by the reviewers. This may be due to the assorted dose and length of treatment of comparative enoxaparin in the trials against a fi xed dose and fi xed length of treatment of the new oral anticoagulant and the type of surgery either total knee or total hip arthroplasty. Not all defi nitions of outcome measurement criteria were the same across all Phase III trials. According to Ageno (2009) , the defi nition of bleeding in the RECORD trials differed for the other new oral anticoagulant Phase III trials. Ageno advises that indirect comparisons on safety profi les of the new anticoagulants must be considered cautiously. Friedman et al. (2010) conducted a pooled analysis for the effi cacy and safety of dabigatran in the RE-MOBILIZE, RE-MODEL, and RE-NOVATE Phase III trials after total hip and knee arthroplasty, and concluded that dabigatran is very similar to enoxaparin, represents a good oral alternative, and had no clinical signifi cant difference related to mortality or for safety. When these same dabigatran trials were examined separately, Trujillo (2011) relays that in the RE-MOBIZE trial, dabigatran was shown to be inferior to enoxaparin for VTE protection.
In regard to rivaroxaban, Agneo (2009) found that rivaroxaban was superior to enoxaparin for VTE prophylaxis and has a similar safety profi le for all RECORD trials. Ufer (2010) indicates that among all of the RECORD trial results, incidence of major bleeding was not signifi cantly different between the rivaroxaban and enoxaparin. However, Van Theil et al. (2009) , in pooled data from all the RECORD trials, concluded that there was a clear and consistent trend for increased major bleeding with rivaroxaban.
Apixaban was compared with enoxaparin in the ADVANCE 1, 2, and 3 Phase III trials. The results for VTE protection were varied and attributed to the altered doses of enoxaparin in the ADVANCE trials (Trujillo, 2011; Ufer, 2010) . In regard to incidence of major bleeding with apixaban, lower bleeding rates were reported for the apixaban group in the ADVANCE 1 trial, nominally lower rates in the ADVANCE 2 trial, and similar rates for ADVANCE 3 trial (Ufer, 2010 ). There were no pooled studies of the ADVANCE trials.
P HARMACODYNAMICS AND P HARMACOKENITICS Dabigatran: Direct Thrombin Inhibitor
The direct thrombin inhibitors are also referred to as factor IIa inhibitors. Thrombin plays a complex role in the coagulation cascade by cleaving fi brinogen to form a fi brin mesh and a clot. The direct thrombin inhibitors inhibit the enzymatic activity of thrombin and inhibit fi brin-bound thrombin, preventing clot formation (Mazza & Yale, 2009 ). Dabigatran prolongs coagulation formation through thrombin inhibition, is specifi c for thrombin, and has little effect on other coagulation factors (Eriksson, Quinlan, & Weitz, 2009 ).
Dabigatran etexilate is a prodrug that is rapidly converted into dabigatran, which is a potent, nonpeptidic small molecule. It directly inhibits both free and clot bound thrombin ). Dabigatran was developed as a prodrug type to facilitate gastrointestinal absorption . A prodrug is the inactive form of a drug that is metabolically converted within the body to the active form of the drug. Although the prodrug dabigatran etexilate is rapidly absorbed, it has low oral bioavailability of approximately 7.2% (Blech, Ebner, Ludwig-Schwellinger, Stangier, & Roth, 2008) . Peak plasma concentrations after administration occurs in about 1.5 hours and steady levels are reached within 3 days of multiple dosing (Stangier, 2008) . The average half-life is about 8 hours (Blech et al., 2008) . The primary site of metabolism of dabigatran occurs in the liver (Tsiara et al., 2011) with 85% excreted in the urine and 6% in feces (Blech et al., 2008) . In Canada and Europe, dabigatran is contraindicated for patients with severe renal failure as defi ned as creatinine clearance (CrCl) of less than 30 mL/min with a modifi ed dose recommended in patients with decreased CrCl ( Eriksson et al., 2007a ) . According to Tsiara et al. (2011) , patients with severe renal failure were not included in the trials for dabigatran. However, there are data from a nonorthopaedic RE-LY trial, indicating that dabigatran is safe for those patients with moderate renal insuffi ciency, as defi ned as CrCl of 30-50 mL/min (Eriksson & Friedman, 2009 ). For patients who are older than 75 years and those with moderate renal failure, it is recommended that the lower dose of dabigatran (150 mg) be administered starting with a half dose the day of surgery (Eriksson & Friedman, 2009 ). There are no data regarding hepatic toxicity, as patients with severe liver disease have also not been included in the dabigatran trials (Sattari & Lowenthal, 2010) . Dabigatran is best absorbed, regardless of food intake, as it contains an acidifying compound to facilitate absorption (Tsiara et al., 2011) .
Rivaroxaban and Apixaban: Factor Xa Inhibitors
Factor Xa is uniquely positioned on the coagulation cascade as a connection between extrinsic and intrinsic pathways ( Bauer, 2008 ; Ma, 2007) . Factor Xa regulates the creation of thrombin by binding to Factor Va, triggering activation of prothrombin to thrombin formation (Ma, 2007; Mazza & Yale, 2009 ) . Thrombin formation leads to the conversion of fi brinogen to fi brin (Sattari & Lowenthal, 2010) . Rivaroxaban and apixaban bind directly to the active Factor Xa site and block chemical interaction with the substrate .
Factor Xa inhibitors are divided into direct and indirect inhibitors. Rivaroxaban is a direct factor inhibitor that interrupts both the intrinsic and extrinsic pathways of the coagulation cascade and inhibits both thrombin formation and the development of clots (Steffel & Lüscher, 2009 ) . Rivaroxaban is available in the active form. The oral bioavailability of rivaroxaban is 80%-100% (Lang, Freudenberger, & Weinz, 2009) , with peak plasma levels reached within 2-4 hours (Gross & Weitz, 2008) . Half-life ranges between 5 and 13 hours, depending on age and renal clearance status . Rivaroxaban is metabolized mainly within the liver with the kidneys excreting two thirds of rivaroxaban and the remainder excreted within the feces Walenga & Adiguzel, 2010 ) . Like dabigatran, CrCl must be considered as rivaroxaban is contraindicated in patients with severe renal impairment and must be carefully monitored in patients with renal insuffi ciency ). In addition, as rivaroxaban is mainly metabolized in the liver, it is also recommended that it be contraindicated in patients with severe hepatic disease ). Rivaroxaban bioavailability is unaffected by food ; however, rivaroxaban is best absorbed at least 2 hours after a meal (Tsiara et al., 2011) .
Apixaban is available in the active form of the drug. Oral bioavailability is approximately 68% with an absorption rate of 1 hour after administration (Raghavan et al., 2009) . Peak levels are reached within 1-3 hours after administration with steady concentrations reached at Day 3 ). The half-life was deemed to be approximately 12 hours (Raghaven et al., 2009) . Apixaban is metabolized mainly within the liver with approximately 49% excreted by the fecal route and 27% eliminated by the renal system (Raghaven et al., 2009 ). Renal and liver disease dose precautions and food timing considerations recommendations were not available.
D RUG AND F OOD I NTERACTIONS OF THE N EW O RAL A NTICOAGULANTS
It is well known that warfarin has numerous drug and food interactions. Patient monitoring and education are necessary to safely treat with this anticoagulant. Multiple drug and food interactions with warfarin are due to hepatic metabolism and with CYP450 enzymatic © 2012 by National Association of Orthopaedic Nurses mediation ( Ansell et al., 2008 ) . Although drug and food interactions are deemed to be less than with warfarin, the new oral anticoagulants target specifi c enzymes within the coagulation cascade and require careful drug and food interaction consideration that are affected by those specifi c enzymatic infl uences ( Ansell et al., 2008 ) .
Dabigatran specifi cally inhibits P-glycoprotein transport (P-gp; Tsiara et al., 2011) . Any other drug that affects P-gp can impact drug-drug interactions. The drugs that are contraindicated concurrently with dabigatran are quinidine, verapamil, and clarithromycin ( Hou, 2011a ; Tsiara et al., 2011) . Quinidine doubles the concentration of dabigatran ( Hou, 2011a ) . Dose reduction is advised for amiodarone when used along with dabigatran. In addition, rifampin and St. John's wort are to be used with caution ( Hou, 2011a ) . It is also advised not to use nonsteroidal anti-infl ammatory agents (NSAIDS) or aspirin in conjunction with dabigatran due to an increased risk of bleeding ( Hou, 2011a ) . The bioavailability of dabigatran decreases when administered with the proton pump inhibitors, as dabigatran's solubility is dependent on an acid environment of pH Ͻ 4 (Walenga & Adiguzel, 2010 ) .
Rivaroxaban is metabolized mainly in the liver via CYP3A4/3A5 and CYP2J2 enzymatic activity ( Hou, 2011a ; Walenga & Adiguzel, 2010 ) . Like dabigatran, it is also affected by P-gp ( Hou, 2011a ) . The CYP3A4 and P-gp inhibitors that increase rivaroxaban's effi ciency and therefore increase bleeding risk are ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, clarithromycin, erythromycin, lopinavir, indinavir, and conivaptan (U.S. Department of Health and Human Services, Food and Drug Administration, 2011b; Walenga & Adiguzel, 2010 ) . Concurrent drugs that potentiate CYP3A4 and P-gp activity and therefore decrease rivaroxaban's effi ciency are rifampicin, carbamazepine, phenytoin, and St. John's wort (U.S. Department of Health and Human Services, Food and Drug Administration, 2011b; Walenga & Adiguzel, 2010 ) . Uses of NSAIDS, anticoagulants, and clopidogrel are also cautioned because of an increase in bleeding risk (U.S. Department of Health and Human Services, Food and Drug Administration, 2011b; Walenga & Adiguzel, 2010 ) . Bleeding risks were noted to increase with the use of opioids or statins in the RECORD rivaroxaban trials but those results were not statistically signifi cant ( Hou, 2011a ) . However, pooled data from the RECORD trials showed no increase in bleeding when rivaroxaban was coadministered with aspirin or with NSAIDS (Walenga & Adiguzel, 2010 ) . For a detailed list of considerations when prescribing and administrating rivaroxaban, refer to Table 4 .
Apixaban like rivaroxaban is mediated by CYP3A4 enzymatic activity (Walenga & Adiguzel, 2010 ) . Specifi c drug interactions with apixaban have not yet identifi ed. However, like rivaroxaban and CYP3A4 metabolism infl uences, the list of contraindicated drugs will most likely include the same drugs that affect rivaroxaban (Walenga & Adiguzel, 2010 ) .
In addition to prescription drug interactions, overthe-counter medications and dietary supplements also have the potential for interactions with the new oral anticoagulants. Careful assessment of prescription medications, over-the-counter medications, and dietary supplements need to be considered, as use of one or more agents concurrently with prescription medication is common. Qato et al. (2008) found, in their study of older adults aged 57-85 years, that 81% used at least 1 prescription medication, 42% used an overthe-counter medication, and 49% used a dietary supplement. Some of the dietary supplements have shown to increase bleeding tendencies such as garlic, the Chinese herb danshen, and vitamin E (Walenga & Adiguzel, 2010 ) .
Generally, noted food interactions with the new oral anticoagulants are few according to Walenga and Adiguzel (2010) . This is a welcome change from the numerous food interactions that need to be considered with warfarin administration. Also, gastrointestinal function should be considered as gastric pH, and intestinal motility and binding can affect absorption and elimination of these new oral anticoagulants (Walenga & Adiguzel, 2010 ) .
For a general comparison of the new anticoagulants, refer to Table 5 .
A NTIDOTES FOR THE N EW O RAL A NTICOAGULANTS
Currently there are no specifi c antidotes to stem bleeding after administration of the new oral anticoagulants (Tsiara et al., 2011) . According to Tsiara et al. (2011) , both warfarin and LMWH have an antidote to reverse anticoagulation activity. Vitamin K specifi cally and effectively reverses the anticoagulation effect of warfarin (Tsiara et al., 2011) . They state that protamine sulfate partially reverses anticoagulation activity of LMWH and that freshfrozen plasma or recombinant factor VII may also be used to reverse anticoagulant effect of LMWH. Prothrombin complex and recombinant factor FVIIa are being studied as possible reversal agents for the new oral anticoagulants but have no suffi cient evidence that they can stop bleeding if necessary (Tsiara et al., 2011) . The new compounds that are being researched to reverse the effects of the new anticoagulants are agents with desmopressin and/or antifi brionolytic activity (Tsiara et al., 2011) .
L ABORATORY M ONITORING
One of the ideal properties of the new oral anticoagulants is that they eliminate the need for laboratory monitoring. Tsiara et al. (2011) caution that monitoring may still be necessary in certain clinical conditions. The authors advise that despite the lack of required laboratory monitoring, clinical supervision remains necessary and includes the following situations: compliance checks with therapy, monitoring the effi cacy and possible overtreatment especially for those with renal or hepatic disease, identifi cation and assessing other concurrent drugs that may effect anticoagulation, the assessment and monitoring for the presence of thrombotic disease and/or treatment failure, assessment and monitoring for severe bleeding complications, and identifi cation of those who are surgical candidates to continue with anticoagulation adequacy if essential.
To measure serum laboratory values, new assays need to be developed for the new anticoagulants. According to Tsiara et al. (2011) , the coagulation assays that are available are inadequate as they are mainly insensitive and correlate weakly to the new oral anticoagulants. According to the authors, thrombin time and ecarin clotting time are currently the most sensitive available tests for monitoring the effects of dabigatran and the antiFXa assay is the most sensitive for rivaroxaban.
C OST C OMPARISONS
In regard to the cost-benefi t of the new oral anticoagulants, Wolowacz et al. (2009) found that dabigatran was more cost-effective than enoxaparin when administered for patients following total knee and total hip arthroplasty surgery and held true even when patients concurrently injected themselves with enoxaparin for the short term. When using dabigatran for more than 30 days, dabigatran was not found to be as cost-effective as enoxaparin. In another study examining cost, McCullagh, Tilson, Walsh, and Barry (2009) compared rivaroxaban against both dabigatran and enoxaparin for cost-effectiveness after total knee and hip arthroplasty. Rivaroxaban was found to be more cost-effective than dabigatran and enoxaparin. There have been no (Tsiara et al., 2011 ).
Summary
Major orthopaedic surgical patients are at high risk for the development of VTE. Current VTE prophylactic methods within the orthopaedic arena have been proven to be effi cacious. However, there are some safety and use inconvenience issues associated with the currently used agents. Orthopaedic surgeons base their choice of VTE prophylactic agents following major orthopaedic surgery on guidelines by the ACCP or the AAOS. Modality choice is determined by the risk-benefi t ratio, which can be diffi cult to interpret because of varying defi nitions and varying outcomes measured between the guidelines. The main safety outcome that orthopaedic surgeons consider is bleeding at the surgical incision or within the joint space after major orthopaedic surgery.
The new oral anticoagulants, dabigatran, rivaroxaban, and apixaban, were developed as specifi c coagulation cascade target inhibitors and tested after total hip and knee arthroplasty in Phase III trials comparing them with enoxaparin. As specifi c inhibitors, they eliminate the broad effect of the currently used agents, especially warfarin. The new oral anticoagulants have demonstrated several advantages, including rapid onset of action, predictable properties, and fi xed dose prescription. These drugs also do not require laboratory monitoring. Dabigatran and rivaroxaban have been deemed to be effi cacious and safe for orthopaedic indications, as they have been approved for orthopaedic use in Europe and in Canada. Currently, rivaroxaban is the only new oral anticoagulant that has been approved by the FDA for use in orthopaedics within the United States. The FDA has approved dabigatran for cardiac indications for those patients with atrial fi brillation. Although tested in trials similar to dabigatran and rivaroxaban, apixaban has not been approved in any country or for any indication.
Concerns persist regarding the new oral anticoagulants with specifi c issues involved in treating those with renal and hepatic toxicity. In those patients with liver disease, it is advised that all the new oral anticoagulants be administered with caution and close monitoring be performed (Walenga & Adiguzel, 2010 ) . Liver disease can have a marked effect on individual response to anticoagulation. Dabigatran and rivaroxaban are contraindicated in those with severe renal failure as the majority of the drug in both is excreted by the renal system ( Hou, 2011a ) . The impact of hepatic and renal disease, and the effect of drug metabolism, must be taken into serious consideration especially when treating the Older adults with the new anticoagulants ( Hou, 2011a ; Walenga & Adiguzel, 2010 ) . Further research will undoubtedly follow as ximelagatran was removed from the European and Canadian markets soon after its release due to hepatic toxicity. More studies regarding complications and safety need to be conducted.
Concurrent use of other medications that affect CYP3A4 and P-pg activity must be considered when administering the new oral anticoagulants. Bleeding concerns remain and must be also addressed when treating with these new agents.
Nursing Implications Prevention of VTE is considered a major component of patient care management in orthopaedics. The recognition of VTE is diffi cult and costly and can present a clinical challenge. Symptoms of VTE many times are unspecifi c and often are asymptomatic . Because of this, nursing needs to understand and promote the use of well-designed tools and guidelines for VTE presence and risk assessment (Welle, 2011) , as it is often the nurse who initially recognizes the presence or risk for VTE. It is important for the nurse to conduct a thorough history and physical assessment, monitor response to treatment, and interpret assays and vital signs to ensure a comprehensive assessment of VTE presence and risk. Rivaroxaban is the fi rst new oral anticoagulant that orthopaedic nurses are currently administrating to their patients. To facilitate and ensure effective patient teaching and safe administration regarding any VTE prophylactic treatment, the nurse must understand the properties of each modality, specifi c target effect on the coagulation cascade, potential complications, drugdrug or drug-food interactions, and necessary monitoring. In order for patients to fully embrace and understand their VTE treatment regimen, it is essential that nurses ensure that patients are partners in the educational process (Morrison, 2006) .
To enhance prevention of VTE, it is also important for nurses to promote collaboration and effective communication among the care team, to understand and embrace new anticoagulant agents and VTE modalities, to participate in the writing of VTE guidelines or risk assessment algorithms, and to actively conduct or participate in research to ensure the best practice (FitzPatrick, Reilly, & Stavroupoulos, 2006; Welle, 2011) . One of the ways in which nursing could enhance understanding of why physicians choose one method of VTE prophylaxis over another is simply to ask. It is important for orthopaedic nurses to familiarize themselves with a summary of the AACP and AAOS guideline recommendations. As stated earlier in this article, bleeding risk is highly regarded by orthopaedic surgeons when choosing a VTE prophylactic modality. Nurses need to be aware of why and how to measure bleeding risks. In addition to the nurse-physician communication, it is important to maintain open channels with pharmacists as they can provide a wealth of information regarding the new oral anticoagulants.
The Institute of Medicine (2010) charges that the professional formation of every nurse must include new competencies in decision making, quality improvement, systems thinking, and team leadership. To achieve optimal outcomes, the Institute of Medicine states that nurses must become full partners with physicians and the healthcare team in redesigning healthcare through open communication, systems analysis, goal establishment, and participating and serving in leadership roles in decision-making policies.
Because new drug research is rapidly advancing, it is important to research and understand new technology and agents to properly assess, monitor, evaluate, and educate. As in the case of the new oral anticoagulants, the embracement of rapidly emerging new treatments will be both challenging and exciting for nurses.
